<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01366287</url>
  </required_header>
  <id_info>
    <org_study_id>B0171006</org_study_id>
    <nct_id>NCT01366287</nct_id>
  </id_info>
  <brief_title>A Study Of PF-03882845 Absorption In Healthy Volunteers Given Orally As Tablet Versus Suspension Formulations And Effect Of Food On Its Absorption</brief_title>
  <official_title>A Randomized, Open-Label, Single Dose, Crossover Study To Estimate The Relative Oral Bioavailability And Food Effect Of PF-03882845 In Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to estimate the relative bioavailability and food effect
      of a PF-03882845 tablet as compared to a suspension formulation used in previous clinical
      studies.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PF-03882845 PK: Cmax, AUCinf, AUClast, Tmax, t1/2, as data permit.</measure>
    <time_frame>predose and post each dose (24, 48 and 96 hour timepoints)</time_frame>
    <description>Post dose is measured at 24, 48 and 96 hours after dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety: Safety labs, vital signs, ECGs, physical examinations and adverse event monitoring.</measure>
    <time_frame>45 days</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Suspension/fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Tablet/fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Tablet/fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-03882845</intervention_name>
    <description>25 mg of PF-03882845 suspension (75% SDD) will be given as a single oral dose under fasted condition</description>
    <arm_group_label>Suspension/fasted</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-03882845</intervention_name>
    <description>25 mg PF-03882845 Tablet (75% SDD) will be given as a single oral dose under fasted condition</description>
    <arm_group_label>Tablet/fasted</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-03882845</intervention_name>
    <description>25 mg PF-03882845 Tablet (75% SDD) will be given as a single oral dose under fed condition</description>
    <arm_group_label>Tablet/fed</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and/or female subjects between the ages of 18 and 55 years,Females must
             be of non-childbearing potential. Body mass index of 17.5 to 30.5 kg/m2.

          -  Subjects who are willing and able to comply with all scheduled visits, treatment plan,
             laboratory tests, and other study procedures.

        Exclusion Criteria:

          -  Serum potassium &gt;5 mEq/L at screening.

          -  Impaired kidney function (estimated GFR &lt;60 mL/min/1.73 m2). History of sensitivity to
             eplerenone, spironolactone, or related compounds.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B0171006&amp;StudyName=A%20Study%20Of%20PF-03882845%20Absorption%20In%20Healthy%20Volunteers%20Given%20Orally%20As%20Tablet%20Versus%20Suspension%20Formulations%20And%20Effect%20Of%20Food%20On%20It</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2011</study_first_submitted>
  <study_first_submitted_qc>June 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2011</study_first_posted>
  <last_update_submitted>June 2, 2011</last_update_submitted>
  <last_update_submitted_qc>June 2, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 6, 2011</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <keyword>Relative bioavailability</keyword>
  <keyword>food effect</keyword>
  <keyword>tablet</keyword>
  <keyword>suspension</keyword>
  <keyword>single dose</keyword>
  <keyword>crossover</keyword>
  <keyword>healthy subjects</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

